Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients

Article Critical Care Medicine

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Cameron R. Wolfe et al.

Summary: In hospitalized patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse events.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Article Immunology

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Susan A. Olender et al.

Summary: In a comparative analysis, remdesivir was found to be associated with significantly higher recovery rates and a 62% reduced mortality rate compared to standard-of-care treatment by day 14 in patients with severe COVID-19.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Andre C. Kalil et al.

Summary: This study compared the efficacy of interferon beta-1a in combination with remdesivir versus remdesivir alone in hospitalised COVID-19 patients. The results showed no significant difference in time to recovery and mortality rate between the interferon beta-1a plus remdesivir group and the placebo plus remdesivir group, with patients requiring high-flow oxygen at baseline having poorer outcomes after interferon beta-1a treatment.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Letter Respiratory System

Steroid use in elderly critically ill COVID-19 patients

Christian Jung et al.

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network

Claire Dupuis et al.

Summary: The study found that early corticosteroid treatment in COVID-19 pneumonia patients was not significantly associated with patient survival, but age and inflammation status can significantly influence the effects of corticosteroids.

PLOS ONE (2021)

Add to Collection

Review Medicine, Research & Experimental

Emerging treatment strategies for COVID-19 infection

Maria Gavriatopoulou et al.

Summary: COVID-19 is a novel emerging infectious disease caused by SARS-CoV-2 originating from Wuhan, China and has led to a worldwide pandemic. The typical manifestations include fever, sore throat, and dyspnea, with supportive care being the current standard of treatment as effective antiviral options are still lacking.

CLINICAL AND EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal